Key points are not available for this paper at this time.
The pharmaceutical industry is in the spotlight nowadays. The financial situation of the pharmaceutical industry has experienced a lot of ups and downs due to the COVID-19. Therefore, analyzing the financial data of the pharmaceutical industry becomes significant. This report looks at three headline companies in the pharmaceuticals industry, Pfizer, Johnson & Johnson and Amgen. By analyzing and comparing their D/E ratio, weighted average cost of capital (WACC) and business risk, this report explores the reasons for the differences in the data of these three companies, forecasts the growth prospects of them and gives relevant advice to investors. The pharmaceutical industry is in the spotlight nowadays. The financial situation of the pharmaceutical industry has experienced a lot of ups and downs due to the COVID-19. Therefore, analyzing the financial data of the pharmaceutical industry becomes significant. This report looks at three headline companies in the pharmaceuticals industry, Pfizer, Johnson & Johnson and Amgen. By analyzing and comparing their D/E ratio, weighted average cost of capital (WACC) and business risk, this report explores the reasons for the differences in the data of these three companies, forecasts the growth prospects of them and gives relevant advice to investors. A basic result turn out to be that Investors should weigh the financial strategies of these companies against their individual risk tolerance and the dynamic landscape of the pharmaceutical industry before making investment decisions.
Miao et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: